Gerold Bepler

Summary

Affiliation: Wayne State University
Country: USA

Publications

  1. pmc Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer
    Gerold Bepler
    Karmanos Cancer Institute, Detroit, MI 48201, USA
    J Clin Oncol 31:2404-12. 2013
  2. pmc ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis
    Gerold Bepler
    Karmanos Cancer Institute, Detroit, Michigan 48201, USA
    Am J Pathol 178:69-78. 2011
  3. pmc Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer
    Gerold Bepler
    Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida, USA
    J Thorac Oncol 6:553-8. 2011
  4. pmc Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer
    Gerold Bepler
    Program and Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida, USA
    J Thorac Oncol 3:1112-8. 2008
  5. ncbi request reprint Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer
    George Simon
    Program and Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    J Clin Oncol 25:2741-6. 2007
  6. ncbi request reprint RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer
    Gerold Bepler
    H Lee Moffitt Cancer Center and Research Institute, MRC 4W, Room 4046, 12902 Magnolia Dr, Tampa, FL 33612 9497, USA
    J Clin Oncol 24:4731-7. 2006
  7. pmc Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer
    Zhong Zheng
    Program and Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9497, USA
    Cancer 112:2765-73. 2008
  8. ncbi request reprint Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer
    Alberto Chiappori
    Thoracic Oncology Program, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Oncology 68:382-90. 2005
  9. doi request reprint Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, MRC 4W, Tampa, FL 33612, USA
    Future Oncol 4:51-9. 2008
  10. doi request reprint Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer
    Tawee Tanvetyanon
    Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    J Clin Oncol 26:4610-6. 2008

Research Grants

  1. RRM1 in the Management of Lung Cancer
    Gerold Bepler; Fiscal Year: 2010

Collaborators

Detail Information

Publications62

  1. pmc Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer
    Gerold Bepler
    Karmanos Cancer Institute, Detroit, MI 48201, USA
    J Clin Oncol 31:2404-12. 2013
    ..We assessed whether chemotherapy selection based on in situ ERCC1 and RRM1 protein levels would improve survival in patients with advanced non-small-cell lung cancer (NSCLC)...
  2. pmc ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis
    Gerold Bepler
    Karmanos Cancer Institute, Detroit, Michigan 48201, USA
    Am J Pathol 178:69-78. 2011
    ..Future trials should incorporate the collection and processing of tumor specimens prospectively on standardized protocols to better reveal the impact of biomarkers on clinically relevant outcomes...
  3. pmc Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer
    Gerold Bepler
    Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida, USA
    J Thorac Oncol 6:553-8. 2011
    ..A reduction in both local and distant recurrence is needed to improve patients' outcome. Performing molecular studies on serially collected tumor specimens may result in a better selection of therapeutic options...
  4. pmc Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer
    Gerold Bepler
    Program and Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida, USA
    J Thorac Oncol 3:1112-8. 2008
    ..The goal was to achieve a disease response rate of 50% and to determine if the expression levels of genes associated with GP metabolism are predictive of response...
  5. ncbi request reprint Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer
    George Simon
    Program and Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    J Clin Oncol 25:2741-6. 2007
    ..We hypothesized that selection of double-agent chemotherapy based on tumoral RRM1 and ERCC1 expression would be feasible and beneficial for patients with advanced NSCLC...
  6. ncbi request reprint RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer
    Gerold Bepler
    H Lee Moffitt Cancer Center and Research Institute, MRC 4W, Room 4046, 12902 Magnolia Dr, Tampa, FL 33612 9497, USA
    J Clin Oncol 24:4731-7. 2006
    ..However, the principal hypothesis that intratumoral levels of gene expression are associated with disease response has not been addressed...
  7. pmc Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer
    Zhong Zheng
    Program and Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9497, USA
    Cancer 112:2765-73. 2008
    ..We hypothesized that intratumoral TS expression would be prognostic of outcome in stage I NSCLC...
  8. ncbi request reprint Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer
    Alberto Chiappori
    Thoracic Oncology Program, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Oncology 68:382-90. 2005
    ..Despite the use of novel chemotherapeutic agents, patients with advanced non-small cell lung cancer (NSCLC) continue to show a poor survival...
  9. doi request reprint Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, MRC 4W, Tampa, FL 33612, USA
    Future Oncol 4:51-9. 2008
    ....
  10. doi request reprint Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer
    Tawee Tanvetyanon
    Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    J Clin Oncol 26:4610-6. 2008
    ....
  11. pmc Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer
    Eric B Haura
    Department of Thoracic Oncology and Biostatistics, Clinical Trials and Clinical Pharmacology Core, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    J Clin Oncol 28:1387-94. 2010
    ....
  12. pmc Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer
    Alberto A Chiappori
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Thorac Oncol 5:484-90. 2010
    ..Our aim was to determine the expression levels of these proteins to assess their potential clinical utility in SCLC...
  13. doi request reprint Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer 112:2021-9. 2008
    ..The primary endpoint was response rate (RR). Secondary endpoints were overall survival (OS) and progression-free survival (PFS)...
  14. ncbi request reprint Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer
    Eric B Haura
    Thoracic Oncology Program and Biostatistics Core, The H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    Clin Cancer Res 11:8288-94. 2005
    ..We evaluated Stat3 activation in early stage non-small cell lung cancers (NSCLC) and how this relates to upstream epidermal growth factor receptor (EGFR) activation, tumor apoptosis, and prognosis...
  15. pmc On Bayesian methods of exploring qualitative interactions for targeted treatment
    Wei Chen
    Department of Oncology, School of Medicine, Wayne State University, Detroit, MI 48201, USA
    Stat Med 31:3693-707. 2012
    ..We illustrate this method in two examples of phase III clinical trials. The algorithm is straightforward and easy to implement using existing software packages. We provide a sample code in Appendix A...
  16. doi request reprint Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer
    Alberto A Chiappori
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 14:1464-9. 2008
    ..This study was designed to assess the influence of atrasentan on paclitaxel pharmacokinetics and to determine the safety and efficacy of atrasentan in combination with paclitaxel-carboplatin...
  17. ncbi request reprint Phase II pharmacogenomics-based adjuvant therapy trial in patients with non-small-cell lung cancer: Southwest Oncology Group Trial 0720
    Gerold Bepler
    Program and Divison of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9497, USA
    Clin Lung Cancer 8:509-11. 2007
  18. pmc ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling
    Smitha Pillai
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida 33612, USA
    Mol Cell Biol 31:3052-67. 2011
    ....
  19. doi request reprint Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer
    Alberto Chiappori
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    J Thorac Oncol 5:369-75. 2010
    ..We examined the efficacy of enzastaurin plus pemetrexed as second-line therapy in patients with advanced (stage IIIA/B or IV) non-small cell lung cancer in a double-blinded, randomized, phase II study...
  20. doi request reprint Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers
    Tawee Tanvetyanon
    Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Thorac Oncol 5:1018-24. 2010
    ..For those undergoing surgery, limited information exists on the relationship between tumor size and survival...
  21. pmc Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer
    Michele L Cote
    Department of Oncology, School of Medicine, Wayne State University, Detroit, Michigan, USA
    J Thorac Oncol 6:627-30. 2011
    ..Mutations occur more commonly in never smokers and East Asians, but there are conflicting reports on the frequency of EGFR mutations in tumors from African Americans...
  22. pmc Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality
    George R Simon
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Int J Biochem Cell Biol 39:1318-28. 2007
    ..This approach is currently being validated in a prospective phase III trial. In the future, assessment of NER function may play a central role in NSCLC treatment decision making...
  23. ncbi request reprint EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer
    Bernadette Ferraro
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, MRC3 E, Room 3056, 12902 Magnolia Dr, Tampa, FL 33612 9497, USA
    J Clin Oncol 23:1921-6. 2005
    ..For these reasons, we hypothesized that reduced levels of EGR1 would correlate with inferior outcome in patients with NSCLC...
  24. ncbi request reprint Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance
    Gerold Bepler
    Thoracic Oncology Program, Lee Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Lung Cancer 47:183-92. 2005
    ..We conclude that clinical studies using RR37 and RR524 for decisions on chemotherapy are premature and that further functional studies on the RRM1 promoter are required to fully elucidate factors controlling RRM1 expression...
  25. pmc Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells
    Jingchun Gao
    Department of Experimental Therapeutics and Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
    Cancer Biol Ther 8:1671-9. 2009
    ..These results suggest that Mirk is overexpressed in lung cancer, acts as a survival factor in lung cancer cells and may be a novel therapeutic target...
  26. pmc A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy
    Jun Zhou
    Molecular Therapeutics Program and Molecular Imaging and Biomarkers Program, Karmanos Cancer Institute, Detroit, MI, USA
    PLoS ONE 8:e58091. 2013
    ..We also conclude that CHK1 inhibition in tumors with low RRM1 levels may be detrimental to gemcitabine efficacy...
  27. pmc Pharmacogenomics: a reality or still a promise?
    Gerold Bepler
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Lung Cancer 54:S3-7. 2006
    ....
  28. ncbi request reprint Neoadjuvant chemotherapy for resectable non-small-cell lung cancer
    Jhanelle Gray
    University of South Florida, Tampa, FL, USA
    Oncology (Williston Park) 23:879-86. 2009
    ..To clarify these issues, well-structured phase III trials comparing adjuvant to neoadjuvant chemotherapy are needed...
  29. ncbi request reprint Molecular analysis-based treatment strategies for non-small cell lung cancer
    Gerold Bepler
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 15:130-9. 2008
    ..Improved understanding in the molecular biology and genetics of lung cancer has resulted in the identification of individual genes, gene expression profiles, and molecular pathways that may be useful for clinical management decisions...
  30. pmc Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers
    Jhanelle E Gray
    Moffitt Cancer Center, Tampa, FL, USA
    Cancer 119:1023-32. 2013
    ..The authors of this report evaluated enzastaurin, a selective protein kinase C-β (PKC-β) inhibitor with antiproliferative and proapoptotic properties, in former smokers...
  31. doi request reprint Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis
    Tawee Tanvetyanon
    Biostatistics Division, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Dr, Tampa, FL 33613, USA
    J Clin Oncol 26:1142-7. 2008
    ..However, some suggest that the survival outcome among patients with a synchronous metastasis is poor. It remains unclear whether this treatment approach is warranted among those with synchronous metastasis...
  32. ncbi request reprint Using translational research to tailor the use of chemotherapy in the treatment of NSCLC
    Gerold Bepler
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    Lung Cancer 50:S13-4. 2005
    ..The discovery of prognostic molecular markers, such as the putative suppressor gene (RRM1), represents a novel and potential parameter to help guide clinical treatment decisions...
  33. ncbi request reprint Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer
    Zhong Zheng
    Thoracic Oncology Program, The H Lee Moffitt Cancer Center and Research Institute, MRC3 East, Room 3056, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
    Chest 128:308-16. 2005
    ..We also hypothesized that EGFR activity may be prognostic for early-stage NSCLC...
  34. ncbi request reprint Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancer
    Nithya Ramnath
    H Lee Moffitt Cancer Center and Research Institute, Thoracic Oncology Program, Tampa, FL 33612, USA
    Chest 128:3467-74. 2005
    ..The primary clinical end point was radiographic disease response rate, and the secondary end points were pathologic response rate, treatment-related toxicity, surgical resectability and outcome, and overall and disease-free survival...
  35. ncbi request reprint RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer
    Gerold Bepler
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    J Clin Oncol 22:1878-85. 2004
    ..It is located in a region of loss of heterozygosity in non-small-cell lung cancer (NSCLC), which is a predictor of poor survival. We hypothesized that RRM1 expression would be a significant predictor of outcome in NSCLC...
  36. doi request reprint Physician referral for fertility preservation in oncology patients: a national study of practice behaviors
    Gwendolyn P Quinn
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Clin Oncol 27:5952-7. 2009
    ..This study examined the referral practices of oncologists in the United States...
  37. pmc Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma
    Ben C Creelan
    Department of Oncologic Sciences, University of South Florida H Lee Moffitt Cancer Center and Research Institute, Tampa, FL MD Anderson Cancer Center, Houston, TX Karmanos Cancer Institute, Wayne State University, Detroit, MI
    J Immunother 36:442-50. 2013
    ..Despite a suggestion of clinical activity in the subset with immune response, the trial did not meet the primary endpoint of inducing radiologic tumor regression. ..
  38. ncbi request reprint Molecular predictors of chemotherapy response in non-small-cell lung cancer
    Jhanelle Gray
    H Lee Moffitt Cancer Center and Research Institute, Division of Thoracic Oncology, Tampa, Florida 33612, USA
    Expert Rev Anticancer Ther 7:545-9. 2007
    ..Recently, how these genes affect lung cancer therapy has been explored in the clinical setting with the goal of finding customized treatment algorithms to optimize efficacy, improve outcomes and minimize toxicity...
  39. ncbi request reprint Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung
    Luke T Nordquist
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Suite 3170, Tampa, FL 33612, USA
    Chest 126:347-51. 2004
    ..Lee Moffitt Cancer Center, and looked for demographic and survival differences in the two groups...
  40. ncbi request reprint Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
    Scott J Antonia
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 12:878-87. 2006
    ....
  41. ncbi request reprint A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer
    Tawee Tanvetyanon
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
    J Thorac Oncol 2:1091-7. 2007
    ..We evaluated available literatures to summarize the state of current knowledge and provide suggestions for future studies...
  42. pmc Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells
    Lei Wang
    Department of Pathology and Cell Biology, University of South Florida, Morsani College of Medicine, Tampa, Florida, United States of America
    PLoS ONE 7:e44265. 2012
    ..In summary, our findings suggest that HDAC6 is positively associated with cisplatin resistance in NSCLC and reveal HDAC6 as a potential novel therapeutic target for platinum refractory NSCLC...
  43. pmc Thymidylate synthase 1 (TS1) in-situ protein expression predicts the survival of Ewing/PNET
    Marilyn M Bui
    Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL 33612 9497, USA
    Fetal Pediatr Pathol 29:385-92. 2010
    ..High TS1 expression, not RRM1 and ERCC1, was associated with long overall survival (p value = 0.057). Thus in-situ TS1 protein expression in Ewing/PNET is a prognostic marker...
  44. ncbi request reprint Antiapoptotic signaling pathways in non-small-cell lung cancer: biology and therapeutic strategies
    Eric B Haura
    Thoracic Oncology and Experimental Therapeutics Programs, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Clin Lung Cancer 6:113-22. 2004
    ....
  45. pmc Modulation of the ribonucleotide reductase M1-gemcitabine interaction in vivo by N-ethylmaleimide
    Zhengming Chen
    Developmental Therapeutics Program, Karmanos Cancer Institute, Detroit, MI 48201, USA
    Biochem Biophys Res Commun 413:383-8. 2011
    ..We conclude that the thiol alkylator NEM can stabilize the gemcitabine-induced conformational change of RRM1, and this stabilized RRM1 conformation has the potential to serve as a specific biomarker of gemcitabine's therapeutic efficacy...
  46. doi request reprint Crizotinib: an anaplastic lymphoma kinase inhibitor
    Shirish M Gadgeel
    Karmanos Cancer Institute, Experimental Therapeutics Program, Wayne State University, 4100 John R, Detroit, MI 48201, USA
    Future Oncol 7:947-53. 2011
    ..Preliminary data suggest that the drug may also be active in tumors with an activated c-Met pathway...
  47. doi request reprint Lung cancer patients' decisions about clinical trials and the theory of planned behavior
    Gwendolyn P Quinn
    Moffitt Cancer Center, University of South Florida, Tampa, FL 33612, USA
    J Cancer Educ 26:641-8. 2011
    ..Results indicate that the theory of planned behavior may be a useful tool to examine psychosocial needs in relation to behavioral intention of clinical trial participation...
  48. ncbi request reprint Expression of TGFbeta type-II receptor in association with markers of proliferation and apoptosis in premalignant lung lesions
    Teresita Munoz-Antonia
    Molecular Oncology Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
    Cancer 110:1527-31. 2007
    ..The authors previously observed that, in head and neck squamous cell carcinoma, the expression of the TGFbeta type II receptor (TbetaR-II) decreases as tumors become less differentiated and more biologically aggressive...
  49. ncbi request reprint Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab
    Jhanelle Gray
    Department of Thoracic Oncology, Yale New Haven Medical Center, New Haven, Connecticut, USA
    J Thorac Oncol 2:571-3. 2007
    ..In this report, we present the first known case of visceral perforation in a patient with metastatic non-small cell lung cancer after treatment with bevacizumab...
  50. ncbi request reprint Malignant pleural mesothelioma: a comprehensive review
    Roohi Ismail-Khan
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 13:255-63. 2006
    ..The incidence of malignant mesothelioma continues to increase, but the disease remains difficult to detect early and treat effectively...
  51. ncbi request reprint Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center Research Institute, Tampa, FL 33612, USA
    Cancer Control 10:388-95. 2003
    ..We conducted an analysis of gefitinib in patients with advanced non-small-cell lung cancer (NSCLC) to assess the antitumor efficacy of this epidermal growth factor receptor tyrosine kinase inhibitor...
  52. ncbi request reprint Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study
    George R Simon
    Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 12:4645-51. 2006
    ..In phase I studies with oral CI-1033, dose-limiting toxicities were primarily gastrointestinal, supporting the exploration of i.v. dosing to achieve optimal drug exposures by increasing bioavailability...
  53. pmc Parameters for individualizing systemic therapy in non-small cell lung cancer
    Shirish M Gadgeel
    Department of Oncology, Wayne State University, MI 48201, USA
    Drug Resist Updat 13:196-204. 2010
    ..Future development will lead to increasing complexity in clinical decision making with substantial anticipated benefits to patients including increased therapeutic efficacy, reduced toxicity, and better quality of life...
  54. pmc Proteomic contributions to personalized cancer care
    John M Koomen
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
    Mol Cell Proteomics 7:1780-94. 2008
    ....
  55. ncbi request reprint Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase
    Ashish Gautam
    Division and Program of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Res 66:6497-502. 2006
    ..We conclude that the regulatory subunit of ribonucleotide reductase has tumor suppressor activity that is mediated through efficient DNA damage repair...
  56. pmc Patient-provider communication and perspectives on smoking cessation and relapse in the oncology setting
    Vani Nath Simmons
    Moffitt Cancer Center, Department of Health Outcomes and Behavior, Tampa, USA
    Patient Educ Couns 77:398-403. 2009
    ..To fill a gap in research by examining cancer patient-provider communication regarding tobacco use and patients' perspectives regarding their experiences with smoking cessation and relapse...
  57. pmc Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006
    Benjamin Djulbegovic
    H Lee Moffitt Cancer Center, 12902 Magnolia Dr, MRC, Room 2067H, Tampa, FL 33612, USA
    Arch Intern Med 168:632-42. 2008
    ..We assessed how often experimental cancer treatments that undergo testing in randomized clinical trials (RCTs) result in discovery of successful new interventions...
  58. pmc A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation
    Donghwa Kim
    Departments of Molecular Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Biol Chem 285:8383-94. 2010
    ....
  59. ncbi request reprint Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition)
    Jhanelle Gray
    Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, MRC 4W, Room 4046, Tampa, FL 33612, USA
    Chest 132:56S-68S. 2007
    ..Chemoprevention is the use of specific agents to reverse, suppress, or prevent the process of carcinogenesis. This article reviews the major agents that have been studied for chemoprevention...
  60. doi request reprint Prognostic and predictive markers for personalized adjuvant therapy for non-small-cell lung cancer patients
    Shirish M Gadgeel
    Department of Oncology, Wayne State University and Molecular Theapeutics Program, Karmanos Cancer Institute, 4100 John R, Mailcode HW02EA, Detroit, MI 48201, USA
    Future Oncol 9:1909-21. 2013
    ..However, most of the available data are retrospective, which limits the utility of these markers in current practice. Ongoing trials are evaluating many promising markers and may guide adjuvant therapy in the future...
  61. ncbi request reprint Lung cancer. Practice organization
    W Michael Alberts
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Chest 123:332S-337S. 2003
    ..Treatment recommendations should be based on locally agreed-on adaptations of clinical practice guidelines. Provisions for ongoing care should be apparent to all concerned..
  62. pmc Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell lines
    Jun Zhou
    Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
    J Nucleic Acids 2010:597098. 2010
    ..The impact of p53 mutations in patients treated with gemcitabine should be studied in prospective clinical trials to develop a model with improved precision of predicting drug efficacy...

Research Grants1

  1. RRM1 in the Management of Lung Cancer
    Gerold Bepler; Fiscal Year: 2010
    ....